• 1. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 2. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 3. An ion-gating multinanochannel system based on a copper-responsive self-cleaving DNAzyme?
  Yang Chen,Di Zhou,Zheyi Meng,Jin Zhai Chem. Commun., 2016,52, 10020-10023
• 4. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 5. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383

Research Briefing on 3-(3,5-Dimethylpiperidin-1-yl)propan-1-amine (CAS: 878657-11-5) in Chemical Biology and Pharmaceutical Applications

3-(3,5-Dimethylpiperidin-1-yl)propan-1-amine (CAS: 878657-11-5) is a structurally unique amine derivative that has garnered significant attention in recent chemical biology and pharmaceutical research. This compound, characterized by its piperidine core and propylamine side chain, has demonstrated promising potential in various therapeutic applications, particularly in the modulation of central nervous system (CNS) targets and as a building block for novel drug candidates.

Recent studies have focused on the compound's role as a key intermediate in the synthesis of sigma receptor ligands. A 2023 publication in the Journal of Medicinal Chemistry highlighted its incorporation into a series of novel sigma-1 receptor modulators, showing enhanced selectivity profiles compared to earlier generations of compounds. The dimethylpiperidine moiety appears to confer optimal steric and electronic properties for receptor binding, while the propylamine linker provides necessary flexibility for target engagement.

In neuropharmacological applications, researchers at several institutions have explored 878657-11-5 as a precursor for potential antidepressant and anxiolytic agents. Preliminary in vivo data presented at the 2023 ACS National Meeting demonstrated that derivatives of this compound exhibited improved blood-brain barrier penetration compared to similar structures with unsubstituted piperidine rings. The 3,5-dimethyl substitution pattern appears to reduce metabolic degradation while maintaining favorable pharmacokinetic properties.

The synthetic accessibility of 3-(3,5-Dimethylpiperidin-1-yl)propan-1-amine has also made it attractive for medicinal chemistry programs. A recent patent application (WO2023187654) describes an optimized synthetic route that achieves the compound in three steps from commercially available 3,5-dimethylpiperidine, with an overall yield of 68%. This improved synthesis has facilitated broader exploration of its derivatives in drug discovery programs.

Emerging research directions include investigations into the compound's potential as a scaffold for antimicrobial agents. A 2024 study in Bioorganic & Medicinal Chemistry Letters reported that certain quaternary ammonium derivatives of 878657-11-5 showed notable activity against Gram-positive pathogens, with MIC values in the low micromolar range. The mechanism appears to involve disruption of bacterial membrane integrity, suggesting possible applications in addressing antibiotic resistance.

From a safety perspective, recent toxicological evaluations of the parent compound have been generally favorable. Acute toxicity studies in rodent models (published in Regulatory Toxicology and Pharmacology, 2023) indicated an LD50 >500 mg/kg via oral administration, with no observed neurobehavioral effects at therapeutic dose ranges. However, researchers caution that specific derivatives may exhibit varying safety profiles depending on their structural modifications.

Future research directions for 3-(3,5-Dimethylpiperidin-1-yl)propan-1-amine appear focused on three main areas: development of more selective CNS modulators, exploration of its potential in pain management therapeutics, and investigation of its utility in targeted drug delivery systems. The compound's versatility and demonstrated biological activity ensure it will remain an important focus of pharmaceutical research in coming years.

• 58324-99-5(3,7-Diazabicyclo[3.3.1]nonane, 3-methyl-)
• 90203-05-7(N,N-Dimethyl-1-piperidin-3-ylmethanamine)
• 724695-93-6(4,4-Piperidinedimethanamine,1-methyl-(9CI))
• 14613-37-7((1-methyl-3-piperidyl)methanamine)
• 14156-91-3(3-(3-Methylpiperidin-1-yl)propan-1-amine)
• 6238-38-6(1-Azabicyclo[2.2.2]octane-3-methanamine,N,N-dimethyl-)
• 909037-18-9(3,7-Dipropyl-3,7-diazabicyclo[3.3.1]nonane)
• 14789-33-4(3,7-Diazabicyclo[3.3.1]nonane,3,7-dimethyl-)
• 254905-65-2((R)-N,N-Dimethyl-1-(piperidin-3-yl)methanamine)
• 120990-84-3(Diethyl-piperidin-3-ylmethyl-amine)